Abstract

Cedrus atlantica is widely used in herbal medicine. However, the anti-cancer activity of C. atlantica extract (CAt extract) has not been clarified in hepatocellular carcinoma. In the study, we elucidated the anti-hepatoma capacity of CAt extract on HCC in vitro and in vivo. To explore the anti-hepatoma mechanisms of the CAt extract in vitro, HCC and normal cells were treated with the CAt extract, which showed marked inhibitory effects on HCC cells in a dose-dependent manner; in contrast, the CAt extract treatment was less cytotoxic to normal cells. In addition, our results indicate that the CAt extract induced apoptosis via caspase-dependent and independent apoptosis pathways. Furthermore, the CAt extract inhibited HCC tumor cell growth by restraining cell cycle progression, and it reduced the signaling of the AKT, ERK1/2, and p38 pathways. In the xenograft model, the CAt extract suppressed HCC tumor cell growth and prolonged lifespan by inhibiting PCNA protein expression, repressing part of the VEGF-induced autocrine pathway, and triggering strong expression of cleaved caspase-3, which contributed to cell apoptosis. Moreover, the CAt extract did not induce any obvious changes in pathological morphology or body weight, suggesting it had no toxicity. CAt extract exerted anti-tumor effects on HCC in vitro and in vivo. Thus, CAt extract could be used as a potential anti-cancer therapeutic agent against HCC.

Highlights

  • Hepatocellular carcinoma (HCC) is the most common type of liver cancer, with an estimated rank of fifth among cancer diagnoses and second among cancer deaths [1]

  • In exploring the potential inhibitory effects of CAt extract against HCC cells, which were treated with a serial dilution of the CAt extract for 24, 48, and 72 h, the results revealed that CAt extract effectively repressed 50% of HCC cell growth at the concentration of 25 μg/mL (Figure 1A)

  • Herbal and plant medicines have been used for centuries worldwide

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, with an estimated rank of fifth among cancer diagnoses and second among cancer deaths [1]. Molecules 2020, 25, 4608 and diet patterns, the incidence and mortality rates of HCC are increasing worldwide [2]. The average survival rate of patients with HCC is less than three months, owing to the majority of patients being diagnosed in an advanced stage [3,4]. There are limited therapeutic options for patients, such as transcatheter arterial chemoembolization (TACE), combination chemo-drugs, and targeted therapy [5]. These palliative treatments suffer from several problems due to their toxicity and associated side effects [6]. It is still urgent to develop a new anti-hepatoma agent for clinical use

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call